Fate Therapeutics, Inc. (FATE)
| Market Cap | 326.37M +173.8% |
| Revenue (ttm) | 6.32M -52.6% |
| Net Income | -129.91M |
| EPS | -1.09 |
| Shares Out | 116.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,015,589 |
| Open | 2.530 |
| Previous Close | 2.490 |
| Day's Range | 2.483 - 2.880 |
| 52-Week Range | 0.910 - 3.230 |
| Beta | 2.55 |
| Analysts | Buy |
| Price Target | 5.41 (+93.21%) |
| Earnings Date | Aug 12, 2026 |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum... [Read more]
Financial Performance
In 2025, Fate Therapeutics's revenue was $6.65 million, a decrease of -51.24% compared to the previous year's $13.63 million. Losses were -$136.32 million, -26.82% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for FATE stock is "Buy." The 12-month stock price target is $5.41, which is an increase of 93.21% from the latest price.
News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s...
Fate Therapeutics announces FDA clearance of FT839 IND application
Fate Therapeutics (FATE) announced that the FDA has cleared its investigational new drug, or IND, application for FT839, the company’s next-generation, off-the-shelf CAR T-cell product candidate engin...
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s...
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ...
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization Accomplished global comm...
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued d...
Fate Therapeutics management to meet with Piper Sandler
Meeting to be held on June 8 hosted by Piper Sandler.
Fate Therapeutics Slides: Corporate presentation
Fate Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illus...
Fate Therapeutics price target raised to $2.20 from $2 at BofA
BofA raised the firm’s price target on Fate Therapeutics (FATE) to $2.20 from $2 and keeps a Neutral rating on the shares. The firm updated its model for Q1 results,…
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent st...
Fate Therapeutics assumed with a Buy at Jefferies
Jefferies assumed coverage of Fate Therapeutics (FATE) with a Buy rating and $4 price target Lead program FAT819 is in Phase 1 for various autoimmune diseases, notes the analyst, who…
Fate Therapeutics reports Q1 EPS (26c), consensus (28c)
Reports Q1 revenue $1.3M, consensus $1.55M. “We are incredibly excited and focused on initiating RECLAIM-LN, our Phase 2 potentially registrational clinical trial of FT819 for the treatment of lupus n...
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initia...
Fate Therapeutics Earnings release: Q1 2026
Fate Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Fate Therapeutics Quarterly report: Q1 2026
Fate Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major ...
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development t...
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent st...
Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Fate Therapeutics (FATE) to $7 from $5 and keeps a Buy rating on the shares. The firm says FT819 continues to demonstrate…
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent st...
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ...
Fate Therapeutics Proxy statement: Proxy filing
Fate Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Fate Therapeutics Proxy statement: Proxy filing
Fate Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.